Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response

Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response

ObjectiveCurrent knowledge on the actions of tofacitinib on cytokine signaling pathways in rheumatoid arthritis (RA) is based on in vitro studies. Our study is the first to examine the effects of tofacitinib treatment on Janus kinase (JAK) - signal transducer and activator of transcription (STAT) pa...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Maaria Palmroth, Krista Kuuliala, Ritva Peltomaa, Anniina Virtanen, Antti Kuuliala, Antti Kurttila, Anna Kinnunen, Marjatta Leirisalo-Repo, Olli Silvennoinen, Pia Isomäki
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: Frontiers Media S.A. 2021-09-01
Cyfres:Frontiers in Immunology
Pynciau:
rheumatoid arthritis
cytokines
JAK inhibitor
monocytes
T cells
B cells
Mynediad Ar-lein:https://www.frontiersin.org/articles/10.3389/fimmu.2021.738481/full

Rhyngrwyd

https://www.frontiersin.org/articles/10.3389/fimmu.2021.738481/full

Eitemau Tebyg